ArticleCureus2025
Volumetric and Linear Imaging Response After Stereotactic Radiotherapy for Vestibular Schwannoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVestibular schwannomas (VS) are benign tumors of the vestibulocochlear nerve. Advances in magnetic resonance imaging (MRI) have increased the detection of smaller lesions, shifting management toward functional preservation. Stereotactic radiotherapy (SRT) delivered as single-fraction stereotactic radiosurgery (SRS), hypofractionated stereotactic radiotherapy (HFSRT), or conventionally fractionated stereotactic radiotherapy (FSRT) achieves high tumor control, but standardized progression criteria and regimen-stratified outcomes remain underexplored.
methodsWe retrospectively reviewed adults with VS treated with SRT (2013-2022). Baseline features, symptoms, and treatment variables were collected. Tumor control was assessed volumetrically (≥20% increase) and linearly (maximum linear diameter (MLD) ≥2 mm) at 12 months, 24 months, and five years. Statistical analyses explored associations with clinical and imaging factors.
resultsAmong 143 patients (median age 58; 84 (59%) female), Koos stage III-IV predominated, present in 104 (73%) patients, 44 (31%) had prior surgery, 86 (60%) had cystic component, and 17 (12%) had T2-weighted hypersignal. Regimens were SRS in 23 (16%), HFSRT in 59 (41%), and FSRT in 61 (43%) patients. The median follow-up was 6.5 years. Baseline symptoms were frequent, reported in 141 (99%) patients, mainly hearing loss (127, 89%) and tinnitus (75, 52%). Volumetric progression declined over time, documented in 25 (22%) patients at 12 months, 18 (15%) at 24 months, and 14 (17%) at five years (p=0.030), while linear rates were stable, occurring in 16 (14%) patients at 12 months, 15 (13%) at 24 months, and 10 (12%) at five years. Both measures correlated strongly (ρ=0.76-0.87). Volumetric progression predicted higher clinical worsening, especially hearing decline at 12 months and five years (p<0.05). Outcomes were comparable at five years across regimens, though SRS showed earlier pseudoprogression at 24 months. Salvage surgery or re-irradiation occurred in eight patients (6%).
conclusionSRT achieved durable control of VS across SRS, HFSRT, and FSRT in this single-institution cohort, with few salvage interventions. The three-axis volumetric criterion (20% increase) outperformed the MLD 2 mm threshold and correlated strongly with contoured gross tumor volume (GTV). Early progression subsided by 24 months, and stability at 12 and 24 months predicted five-year control. Between-regimen divergence at 24 months was consistent with SRS-driven pseudoprogression, with five-year progression remaining similar across regimens. Baseline imaging offered limited prognostic value, whereas clinical worsening, mainly hearing decline, correlated with volumetric progression. Annual MRI after year 1 is generally adequate, with tighter intervals reserved for selected patients. Prospective, audiometry-standardized studies are warranted for validating hearing-related endpoints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.